kynurenine has been researched along with Multiple Myeloma in 5 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we investigated the clinical impact of aberrant Trp metabolism in patients with multiple myeloma (MM) treated with lenalidomide (Len) and evaluated its effects on T cell immunity ex vivo." | 4.31 | Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients. ( Asano, A; Hagiwara, S; Hirade, K; Iida, S; Inagaki, H; Kinoshita, S; Komatsu, H; Kusumoto, S; Maeda, Y; Marumo, Y; Masaki, A; Nakashima, T; Narita, T; Ri, M; Suzuki, T; Tachita, T, 2023) |
| "Oncogenic drivers of progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) such as c-MYC have downstream effects on intracellular metabolic pathways of clonal plasma cells (PCs)." | 1.56 | Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma. ( Broniowska, K; Bush, AG; Gonsalves, WI; Gransee, J; Hitosugi, T; Jessen, E; Kumar, SK; Lacy, MQ; Petterson, XM, 2020) |
| "Weight loss is the main symptom of so-called tumor cachexia." | 1.29 | Weight loss in patients with hematological neoplasias is associated with immune system stimulation. ( Denz, H; Fuchs, D; Herrmann, R; Huber, P; Orth, B; Wachter, H; Weiss, G, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, A | 3 |
| Ri, M | 3 |
| Masaki, A | 3 |
| Maeda, Y | 3 |
| Tachita, T | 3 |
| Hirade, K | 3 |
| Marumo, Y | 3 |
| Nakashima, T | 3 |
| Hagiwara, S | 3 |
| Kinoshita, S | 3 |
| Suzuki, T | 3 |
| Narita, T | 3 |
| Kusumoto, S | 3 |
| Komatsu, H | 3 |
| Inagaki, H | 3 |
| Iida, S | 3 |
| Ray, A | 1 |
| Song, Y | 1 |
| Du, T | 1 |
| Tai, YT | 1 |
| Chauhan, D | 1 |
| Anderson, KC | 1 |
| Gonsalves, WI | 1 |
| Broniowska, K | 1 |
| Jessen, E | 1 |
| Petterson, XM | 1 |
| Bush, AG | 1 |
| Gransee, J | 1 |
| Lacy, MQ | 1 |
| Hitosugi, T | 1 |
| Kumar, SK | 1 |
| CREPALDI, G | 1 |
| PARPAJOLA, A | 1 |
| Denz, H | 1 |
| Orth, B | 1 |
| Weiss, G | 1 |
| Herrmann, R | 1 |
| Huber, P | 1 |
| Wachter, H | 1 |
| Fuchs, D | 1 |
5 other studies available for kynurenine and Multiple Myeloma
| Article | Year |
|---|---|
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lenalidomide; Multiple Myeloma; Tryptophan | 2023 |
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lenalidomide; Multiple Myeloma; Tryptophan | 2023 |
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lenalidomide; Multiple Myeloma; Tryptophan | 2023 |
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lenalidomide; Multiple Myeloma; Tryptophan | 2023 |
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lenalidomide; Multiple Myeloma; Tryptophan | 2023 |
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lenalidomide; Multiple Myeloma; Tryptophan | 2023 |
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lenalidomide; Multiple Myeloma; Tryptophan | 2023 |
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lenalidomide; Multiple Myeloma; Tryptophan | 2023 |
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lenalidomide; Multiple Myeloma; Tryptophan | 2023 |
Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.
Topics: B7-H1 Antigen; Bone Marrow; Cell Line, Tumor; Dendritic Cells; Humans; Killer Cells, Natural; Kynure | 2020 |
Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma.
Topics: Amino Acids, Branched-Chain; Diagnosis, Differential; Humans; Kynurenine; Lactosylceramides; Lipidom | 2020 |
EXCRETION OF TRYPTOPHAN METABOLITES IN DIFFERENT FORMS OF HAEMOBLASTOSIS.
Topics: Cortisone; Cyclophosphamide; Genetic Diseases, X-Linked; Hodgkin Disease; Humans; Kynurenic Acid; Ky | 1964 |
Weight loss in patients with hematological neoplasias is associated with immune system stimulation.
Topics: Biomarkers; Biopterins; Cachexia; Female; Follow-Up Studies; Humans; Immunity, Cellular; Interferon- | 1993 |